D-Penicillamine for preventing retinopathy of prematurity in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Qureshi, Mosarrat J ^a   Kumar, Manoj ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLAMINE; CHELATING AGENT;

CHILD DEATH; DEVELOPMENTAL DELAY; DISEASE SEVERITY; FOLLOW UP; HUMAN; INCIDENCE; INFANT; MORBIDITY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; RISK; SPASTICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; META ANALYSIS; NEWBORN; RETROLENTAL FIBROPLASIA; RETINOPATHY OF PREMATURITY;

CHELATING AGENTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PENICILLAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOPATHY OF PREMATURITY;

EID: 84898755471     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001073.pub2     Document Type: Review

References (56)

1. Lakatos L, Hatvani I, Oroszlan G, Balla G, Karmazsin L, Alaka O, et al.Controlled trial of D-penicillamine to prevent retinopathy of prematurity. Acta Paediatrica Hungary 1986;27(1):47-56.
2. Vekerdy-Lakatos S, Lakatos L, Oroszlan G, Itzes B. One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period. Acta Paediatrica Hungary 1987;28(1):9-16.
3. Lakatos L, Lakatos Z, Hatvani I, Oroszlan G. Controlled trial of use of D-penicillamine to prevent retinopathy of prematurity in very low-birth-weight infants. In: Stern L, Oh W, Friis-Hansen B editor(s). Physiologic Foundations of Perinatal Care. Vol. 2, New York: Elsevier, 1987:9-23.
4. Tandon M, Dutta S, Dogra MR, Gupta A. Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomised, placebo-controlled trial. Acta Paediatrica 2010;99(9):1324-8. [DOI: 10.1111/j.1651-2227.2010.01837.x]
5. Christensen RD, Alder SC, Richards SC, Horn JT, Lambert DK, Baer VL. A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. Journal of Perinatology 2006;26(2):120-4. [DOI: 10.1038/sj.jp.7211440]
6. Christensen RD, Alder SC, Richards SC, Lambert DK, Schmutz N, Wiedmeier SE, et al.D-Penicillamine administration and the incidence of retinopathy of prematurity. Journal of Perinatology 2007;27(2):103-11. [DOI: 10.1038/sj.jp.7211653]
7. Lakatos L, Hatvani I, Karmazsin L. Is the treatment of prematurely born infants with D-penicillamine decreasing the frequency of retrolental fibroplasia? [In Hungarian]. Szemeszet Ophthalmologica Hungarica 1980;117(1):9-12.
8. Lakatos L. Antioxidant effects of d-penicillamine in the neonatal period. Magyar Pediater 1982;16:355-62.
9. Lakatos L, Hatvani I, Karmazsin L, Oroszlan G. Prevention of retrolental fibroplasia in very low birth weight infants by D penicillamine. European Journal of Pediatrics 1982;138(2):199-200.
10. Lakatos L, Hatvani I, Oroszlan GY, Karmazsin L, Matkovics B. Prevention of retrolental fibroplasia with D-penicillamine [In Hungarian]. Gyermekgyogyaszat 1981;32:525-30.
11. Oroszlán G, Lakatos L, Karmazsin L. Neonatal oxygen toxicity and its prevention: D-penicillamine offers benefits without harmful side-effects. Acta Paediatrica Academiae Scientiarum Hungaricae 1982;23(4):459-71.
12. Lakatos L, Hatvani I, Oroszlan G, Karmazsin L, Matkovics B. D-penicillamine in the prevention of retrolental fibroplasia. Acta Paediatrica Academiae Scientiarum Hungaricae 1982;23(4):327-35.
13. Lakatos L, Hatvani I. Penicillamine, vitreous proliferation, and retinopathy of prematurity. American Journal Ophthalmology 1982;93(5):662.
14. Lakatos L, Hatvani I, Oroszlan GY, Vekerdy ZS. Clinical observations in the prevention of retrolental fibroplasia with D-penicillamine. In: Stern L, Xanthou M, Friis-Hansen B editor(s). Physiologic Foundations of Perinatal Care. New York: Praeger, 1985:293-305.
15. Lakatos L. D-penicillamine and retinopathy of prematurity [letter]. Pediatrics 1988;82(6):951-2.
16. Lakatos L, Oroszlan G, Lakatos Z. D-penicillamine in the neonatal period. In: Stern L, Orzalesi M, Friis-Hansen B editor(s). Physiologic Foundations of Perinatal Care. New York: Elsevier, 1989:188-97.
17. Aiello LP. Vascular endothelial growth factor and the eye -past, present, and future. Archives of Ophthalmology 1996;114(10):1252-4.
18. Aiello LP. Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Investigative Ophthalmology & Visual Science 1997;38(9):1647-52.
19. American Heart Association, American Academy of Pediatrics. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: neonatal resuscitation guidelines. Pediatrics 2006;117(5):e1029-e1038.
20. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 2010;125(6):e1483-92. [DOI: 10.1542/peds.2009-2218]
21. Soll RF, Bracken MB, Horbar JD, Ohlsson A, Suresh G, Haughton DE. Cochrane Neonatal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs). NEONATAL 2011, issue 3.
22. Phelps DL, Lakatos L, Watts JL. D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001073]
23. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome -structure and function. Archives of Ophthalmology 1990;108(10):1408-16.
24. Drosos AA, Geogriou P, Politi EN, Voulgari PV. D-penicillamine in early rheumatoid arthritis. Clinical and Experimental Rheumatology 1997;15(5):580-1.
25. Flynn JT, Bancalari E, Bawol R, Goldberg R, Cassady J, Schiffman J, et al.Retinopathy of prematurity: a randomised, prospective trial of transcutaneous oxygen monitoring. Ophthalmology 1987;94(6):630-8.
26. Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomised trial. Transactions of the American Ophthalmological Society 2004;102:233-8; discussion 248-50.
27. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. New England Journal of Medicine 2012;367(26):2515-26. [DOI: 10.1056/NEJMra1208129]
28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [DOI: 10.1136/bmj.d5928]
29. Hunt JT, Lee VG, Liu ECK, Moreland S, McMullen D, Webb ML, et al.Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. International Journal of Peptide and Protein Research 1993;42(3):249-58.
30. An International Committee for the Classification of Retinopathy of Prematurity. The Committee for the Classification of Retinopathy of Prematurity. Archives of Ophthalmology 1984;102(8):1130-4.
31. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology 2005;123(7):991-9.
32. Kinsey V. Retrolental fibroplasia: cooperative study of retrolental fibroplasia and the use of oxygen. Archives of Ophthalmology 1956;56(4):481-547.
33. Koranyi G, Kovacs J, Voros I. D-Penicillamine treatment of hyperbilirubinaemia in preterm infants. Acta Paediatrica Academiae Scientiarum Hungaricae 1978;19(1):9-16.
34. Kukovetz WR, Beubler E, Kreuzig F, Moritz AJ, Nirnberger G, Werner-Breitenecker L. Bioavailability and pharmacokinetics of D-penicillamine. Journal of Rheumatology 1983;10(1):90-4.
35. Lakatos L, Kover B, Vekerdy S, Dvoracsdk E. D-Penicillamine therapy in neonatal jaundice: comparison with phototherapy. Acta Paediatrica Academiae Scientiarum Hungaricae 1976;17(2):93-102.
36. Lakatos L, Kover B, Oroszlan G, Vekerdy Z. D-Penicillamine therapy in ABO haemolytic disease of the newborn infant. European Journal of Pediatrics 1976;123(2):133-7.
37. Lee SJ, Kim SY, Yoo B, Kim H, Kim Y. Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. Investigative Ophthalmology & Visual Science 2011;52:Abstract 3165.
38. Matsubara T, Saura R, Hirohata K, Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. Journal of Clinical Investigation 1989;83(1):158-67.
39. Matsuyama K, Ogata N, Matsuoka M Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium derived factor before and after intravitreal injection of bevacizumab. British Journal of Ophthalmology 2010;94:1215-8.
40. McBrien NA, Norton TT. Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Experimental Eye Research 1994;59(4):475-86.
41. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efflcacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine 2011;364(7):603-15.
42. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al.The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;98(11):1628-40.
43. Phelps DL, Watts JL. Early light reduction to prevent retinopathy of prematurity in very low birth weight infants. Cochrane Database of Systematic Reviews 1997, Issue 1. [DOI: 10.1002/14651858.CD000122]
44. Pietraforte D, Mallozzi C, Scorva G, Minetti M. Role of thiols in the targeting of S-nitroso thiols to red blood cells. Biochemistry 1995;34(21):7177-85.
45. Pinter R, Hogge WA, McPherson E. Infant with severe penicillamine embryopathy born to a woman with Wilson disease. American Journal of Medical Genetics. Part A 2004;128A(3):294-8. [DOI: 10.1002/ajmg.a.10871]
46. Raju TNK, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity -a reappraisal of published trials. Journal of Pediatrics 1997;131(6):844-50.
47. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
48. Sanderud J, Oroszlan G, Bjoro K, Kumlin M, Saugstad OD. D-penicillamine inhibits the action of reactive oxygen species in the pig pulmonary circulation. Journal of Perinatal Medicine 1995;23(5):385-93.
49. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al.Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. American Journal of Ophthalmology 2012;153(2):327-33.
50. Saugstad OD, Hallman M, Abraham JL, Epstein B, Cochrane C, Gluck L. Hypoxanthine and oxygen induced lung injury: a possible basic mechanism of tissue damage?. Pediatric Research 1984;18(6):501-4.
51. Siemeister G, Schnurr B, Mohrs K, Schachtele C, Marme D, Martiny-Baron G. Expression of biologically active isoforms of the tumour angiogenesis factor VEGF in Escherichia coli. Biochemical and Biophysical Research Communications 1996;222(2):249-55.
52. Spandau U, Tomic Z, Ewald U, Larsson E, Akerbolm H, Holmstrom G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?. Acta Ophthalmologica 2012;91(2):170-5.
53. Staite ND, Zoschke DC, Messner RP. Scavenging of hydrogen peroxide -a new mechanism of action for D-penicillamine in rheumatoid arthritis. New England Journal of Medicine 1984;311(8):538-9.
54. STOP-ROP Multicenter Trial. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomised, controlled trial. I: primary outcomes. Pediatrics 2000;105(2):295-310.
55. Vekerdy-Lakatos S, Lakatos L, Oroszlán G, Itzés B. One year longitudinal follow up of premature infants treated with D-Penicillamine in the neonatal period. Acta Paediatrica Hungarica 1987;28(1):9-16.
56. Yoshida D, Ikeda Y, Nakazawa S. Copper chelation inhibits tumour angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995;37(2):287-92.